Development of gout in people with asymptomatic hyperuricemia: study protocol for a 5-year prospective cohort
Introduction The central biochemical cause of gout is hyperuricemia (elevated serum urate levels). Ultrasound features of monosodium urate (MSU) crystal deposition are common in people with asymptomatic hyperuricemia. However, it is unclear whether this is a precondition for the development of gout....
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-11-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/11/e090415.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850194555965538304 |
|---|---|
| author | Maria-Antonietta D’Agostino Tuhina Neogi Hilde Berner Hammer Lene Terslev Lisa Stamp Tony Merriman Sarah Stewart Nicola Dalbeth Anne Horne John D Fitzgerald Mariano Andrés Tristan Pascart Janitzia Vázquez-Mellado Greg Gamble William Taylor Julia Martin Changgui Li Borislav Mihov Mingshu Sun Eleonora Norkuviene Isabel Su Maria-Luisa Peral-Garrido Tillman Uhlig |
| author_facet | Maria-Antonietta D’Agostino Tuhina Neogi Hilde Berner Hammer Lene Terslev Lisa Stamp Tony Merriman Sarah Stewart Nicola Dalbeth Anne Horne John D Fitzgerald Mariano Andrés Tristan Pascart Janitzia Vázquez-Mellado Greg Gamble William Taylor Julia Martin Changgui Li Borislav Mihov Mingshu Sun Eleonora Norkuviene Isabel Su Maria-Luisa Peral-Garrido Tillman Uhlig |
| author_sort | Maria-Antonietta D’Agostino |
| collection | DOAJ |
| description | Introduction The central biochemical cause of gout is hyperuricemia (elevated serum urate levels). Ultrasound features of monosodium urate (MSU) crystal deposition are common in people with asymptomatic hyperuricemia. However, it is unclear whether this is a precondition for the development of gout. This study aims to determine whether ultrasound imaging evidence of MSU crystal deposition predicts development of symptomatic gout over 5 years, in people who already have an increased risk of gout due to elevated serum urate concentrations (≥8 mg/dL).Methods and analysis This is a prospective, international, multicentre study. The study population comprises over 250 participants with asymptomatic hyperuricemia (serum urate ≥8.0 mg/dL). After the baseline assessments, participants are followed for 5 years or until the development of gout, defined by the 2015 American College of Rheumatology/European Alliance of Associations for Rheumatology gout classification criteria. Baseline assessments include anthropomorphic measures, laboratory tests, questionnaires, blood and urine specimen collection, plain radiographs of the feet and standardised ultrasound scans of the lower limbs, scored according to the Outcomes in Rheumatology (OMERACT) gout ultrasound scoring system. The primary outcomes are the development of gout and time course for development of gout in people with and without ultrasound evidence of MSU crystal deposition. Exploratory analyses will examine clinical, genetic and biological factors associated with development of MSU crystal deposition and gout.Ethics and dissemination This study protocol was approved by the New Zealand Ministry of Health Southern Health and Disability Ethics Committee (MEC/05/10/130/AM16) on 18 December 2018. The findings from this study will be published in peer-reviewed journals and will be presented at national and international conferences.Trial registration number ACTRN12619000915156. |
| format | Article |
| id | doaj-art-c7bf9cd82f1c4b178d759a3ac08825e9 |
| institution | OA Journals |
| issn | 2044-6055 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-c7bf9cd82f1c4b178d759a3ac08825e92025-08-20T02:13:58ZengBMJ Publishing GroupBMJ Open2044-60552024-11-01141110.1136/bmjopen-2024-090415Development of gout in people with asymptomatic hyperuricemia: study protocol for a 5-year prospective cohortMaria-Antonietta D’Agostino0Tuhina Neogi1Hilde Berner Hammer2Lene Terslev3Lisa Stamp4Tony Merriman5Sarah Stewart6Nicola Dalbeth7Anne Horne8John D Fitzgerald9Mariano Andrés10Tristan Pascart11Janitzia Vázquez-Mellado12Greg Gamble13William Taylor14Julia Martin15Changgui Li16Borislav Mihov17Mingshu Sun18Eleonora Norkuviene19Isabel Su20Maria-Luisa Peral-Garrido21Tillman Uhlig2218 Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Roma, Italy10 Boston University School of Medicine, Boston, Massachusetts, USA15 Diakonhjemmet Hospital, Oslo, Norway14 Rigshospitalet, Kobenhavn, Denmark6 Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand5 School of Medical Sciences, University of Otago, Dunedin, New Zealand1 Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland, New Zealand4 The University of Auckland Faculty of Medical and Health Sciences, Auckland, New Zealand2 Department of Medicine, The University of Auckland Faculty of Medical and Health Sciences, Auckland, New Zealand13 Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA8 Alicante Institute for Health and Biomedical Research, Alicante, Spain7 Department of Rheumatology, Lille Catholic University, Lille, France12 General Hospital of Mexico, Ciudad de Mexico, Mexico2 Department of Medicine, The University of Auckland Faculty of Medical and Health Sciences, Auckland, New Zealand3 Rehabilitation Teaching & Research Unit, Department of Medicine, University of Otago Wellington, Wellington, New Zealand19 Auckland District Health Board, Auckland, New Zealand21 Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China4 The University of Auckland Faculty of Medical and Health Sciences, Auckland, New Zealand20 Qingdao University, Qingdao, Shandong, China11 Lithuanian University of Health Sciences, Kaunas, Lithuania4 The University of Auckland Faculty of Medical and Health Sciences, Auckland, New Zealand9 Vinalopó University Hospital, Elche, Spain17 Universitetet i Oslo, Oslo, NorwayIntroduction The central biochemical cause of gout is hyperuricemia (elevated serum urate levels). Ultrasound features of monosodium urate (MSU) crystal deposition are common in people with asymptomatic hyperuricemia. However, it is unclear whether this is a precondition for the development of gout. This study aims to determine whether ultrasound imaging evidence of MSU crystal deposition predicts development of symptomatic gout over 5 years, in people who already have an increased risk of gout due to elevated serum urate concentrations (≥8 mg/dL).Methods and analysis This is a prospective, international, multicentre study. The study population comprises over 250 participants with asymptomatic hyperuricemia (serum urate ≥8.0 mg/dL). After the baseline assessments, participants are followed for 5 years or until the development of gout, defined by the 2015 American College of Rheumatology/European Alliance of Associations for Rheumatology gout classification criteria. Baseline assessments include anthropomorphic measures, laboratory tests, questionnaires, blood and urine specimen collection, plain radiographs of the feet and standardised ultrasound scans of the lower limbs, scored according to the Outcomes in Rheumatology (OMERACT) gout ultrasound scoring system. The primary outcomes are the development of gout and time course for development of gout in people with and without ultrasound evidence of MSU crystal deposition. Exploratory analyses will examine clinical, genetic and biological factors associated with development of MSU crystal deposition and gout.Ethics and dissemination This study protocol was approved by the New Zealand Ministry of Health Southern Health and Disability Ethics Committee (MEC/05/10/130/AM16) on 18 December 2018. The findings from this study will be published in peer-reviewed journals and will be presented at national and international conferences.Trial registration number ACTRN12619000915156.https://bmjopen.bmj.com/content/14/11/e090415.full |
| spellingShingle | Maria-Antonietta D’Agostino Tuhina Neogi Hilde Berner Hammer Lene Terslev Lisa Stamp Tony Merriman Sarah Stewart Nicola Dalbeth Anne Horne John D Fitzgerald Mariano Andrés Tristan Pascart Janitzia Vázquez-Mellado Greg Gamble William Taylor Julia Martin Changgui Li Borislav Mihov Mingshu Sun Eleonora Norkuviene Isabel Su Maria-Luisa Peral-Garrido Tillman Uhlig Development of gout in people with asymptomatic hyperuricemia: study protocol for a 5-year prospective cohort BMJ Open |
| title | Development of gout in people with asymptomatic hyperuricemia: study protocol for a 5-year prospective cohort |
| title_full | Development of gout in people with asymptomatic hyperuricemia: study protocol for a 5-year prospective cohort |
| title_fullStr | Development of gout in people with asymptomatic hyperuricemia: study protocol for a 5-year prospective cohort |
| title_full_unstemmed | Development of gout in people with asymptomatic hyperuricemia: study protocol for a 5-year prospective cohort |
| title_short | Development of gout in people with asymptomatic hyperuricemia: study protocol for a 5-year prospective cohort |
| title_sort | development of gout in people with asymptomatic hyperuricemia study protocol for a 5 year prospective cohort |
| url | https://bmjopen.bmj.com/content/14/11/e090415.full |
| work_keys_str_mv | AT mariaantoniettadagostino developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT tuhinaneogi developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT hildebernerhammer developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT leneterslev developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT lisastamp developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT tonymerriman developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT sarahstewart developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT nicoladalbeth developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT annehorne developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT johndfitzgerald developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT marianoandres developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT tristanpascart developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT janitziavazquezmellado developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT greggamble developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT williamtaylor developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT juliamartin developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT changguili developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT borislavmihov developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT mingshusun developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT eleonoranorkuviene developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT isabelsu developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT marialuisaperalgarrido developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort AT tillmanuhlig developmentofgoutinpeoplewithasymptomatichyperuricemiastudyprotocolfora5yearprospectivecohort |